Clinical Trials Using Dasatinib

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Dasatinib. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-25 of 33
1 2 Next >

  • NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma

    This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
    Location: 1160 locations

  • Combination Chemotherapy in Treating Young Patients with Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

    This randomized phase III trial studies how well combination chemotherapy works in treating young patients with newly diagnosed B acute lymphoblastic leukemia that is likely to come back or spread, and in patients with Philadelphia chromosome (Ph)-like tyrosine kinase inhibitor (TKI) sensitive mutations. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) and giving the drugs in different doses and in different combinations may kill more cancer cells.
    Location: 195 locations

  • Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients with Acute Lymphoblastic Leukemia

    This phase II trial studies the side effects and how well blinatumomab and combination chemotherapy or dasatinib, prednisone, and blinatumomab work in treating older patients with acute lymphoblastic leukemia. Monoclonal antibodies, such as blinatumomab, find cancer cells and help kill them. Drugs used in chemotherapy, such as prednisone, vincristine sulfate, methotrexate, and mercaptopurine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving blinatumomab with combination chemotherapy or dasatinib and prednisone may kill more cancer cells.
    Location: 158 locations

  • An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer

    The purpose of this study is to determine whether Nivolumab, in combination with other therapies, is effective in patients with advanced Non-Small Cell lung cancer
    Location: 23 locations

  • Risk Classification Schemes in Identifying Better Treatment Options for Children and Adolescents with Acute Lymphoblastic Leukemia

    This randomized phase III trial studies risk classification schemes in identifying better treatment options for children and adolescents with acute lymphoblastic leukemia. Risk factor classification may help identify how strong treatment should be for patients with acute lymphoblastic leukemia.
    Location: 5 locations

  • Dasatinib in Combination with Chemotherapy in Treating Younger Patients with Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia

    This phase I trial studies the side effects and best dose of dasatinib when given together with combination chemotherapy in treating patients with acute myeloid leukemia that has a genetic mutation (core binding factor), and has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fludarabine phosphate, cytarabine, and idarubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving dasatinib together with combination chemotherapy may be a better treatment for core binding factor acute myeloid leukemia.
    Location: 7 locations

  • TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

    The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers).
    Location: 6 locations

  • A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL

    The design of a phase I, open label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent ABL001 in CML and Ph+ ALL patients who are relapsed or refractory to or are intolerant of TKIs, and of ABL001+Nilotinib, ABL001+Imatinib and ABL001+Dasatinib in Ph positive CML patients who are relapsed or refractory to TKIs.
    Location: 5 locations

  • Targeted Therapy in Treating Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

    This phase II trial studies how well targeted therapy works in treating patients with acute lymphoblastic leukemia or acute myelogenous leukemia that has come back after a period of improvement or does not respond to treatment. Testing patients' blood or bone marrow to find out if their type of cancer may be sensitive to a specific drug may help doctors choose more effective treatments. Dasatinib, nilotinib, sunitinib malate, sorafenib tosylate, and ponatinib hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving targeted therapy based on cancer type may be an effective treatment for acute lymphoblastic leukemia or acute myelogenous leukemia.
    Location: 4 locations

  • Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

    A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma.
    Location: 3 locations

  • Intensive Combination Chemotherapy and Liposomal Cytarabine in Treating Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

    This partially randomized phase II trial studies how well intensive combination chemotherapy and liposomal cytarabine (a form of the anticancer drug cytarabine that is contained inside very tiny, fat-like particles) work in treating patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as daunorubicin hydrochloride, cyclophosphamide, vincristine sulfate, prednisone, leucovorin calcium, cytarabine, etoposide, and liposomal cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Biological therapies, such as mercaptopurine, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Pegaspargase, methotrexate, dasatinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy with, rituximab, mercaptopurine, pegaspargase, methotrexate, dasatinib and imatinib mesylate may be an effective treatment for acute lymphoblastic leukemia or lymphoblastic lymphoma.
    Location: 4 locations

  • Ixazomib Citrate and Combination Chemotherapy in Treating Older Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

    This phase I trial studies the side effects and best dose of ixazomib citrate when given together with combination chemotherapy in treating older patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in combination chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ixazomib citrate with combination chemotherapy may work better in treating older patients with acute lymphoblastic leukemia or lymphoblastic lymphoma.
    Location: 2 locations

  • Dasatinib in Preventing Second Primary Breast Cancer in Women with Estrogen Receptor Negative Breast Cancer

    This randomized phase II trial studies how well dasatinib works in preventing breast cancer from developing in the unaffected breast (second primary breast cancer) in women with estrogen receptor negative breast cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of dasatinib may keep cancer from forming in patients at increased risk for second primary breast cancer.
    Location: 2 locations

  • Dasatinib and Everolimus in Treating Children with Newly Diagnosed, Recurrent, or Progressive High-Grade Glioma with PDGFR / FGFR Alterations

    This phase II trial studies how well dasatinib and everolimus work in treating children with high-grade glioma with PDGFR / FGFR alterations that is newly diagnosed, has come back, or is growing, spreading or getting worse. Dasatinib and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

  • Combination Chemotherapy in Treating Patients with Acute Lymphoblastic Leukemia or Lymphoma

    This randomized phase II / III trial studies the side effects of combination chemotherapy and how well it works in treating patients with acute lymphoblastic leukemia or lymphoma. Drugs used in combination chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: St. Jude Children's Research Hospital, Memphis, Tennessee

  • Ganitumab and Dasatinib in Treating Patients with Relapsed or Refractory Embryonal or Alveolar Rhabdomyosarcoma

    This phase I / II trial studies the side effects and best dose of dasatinib when given together with ganitumab or to see how well they work in treating patients with embryonal and alveolar rhabdomyosarcoma that has come back or does not respond to treatment. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as ganitumab, may block tumor growth in different ways by targeting certain cells. Giving dasatinib and ganitumab may work better in treating patients with embryonal and alveolar rhabdomyosarcoma.
    Location: 2 locations

  • Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

    This phase II trial studies how well etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin (DA-EPOCH) works in treating patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Dasatinib and Osimertinib in Treating Patients with Advanced Non-small Cell Lung Cancer with EGFR Mutations

    This phase I / II trial studies side effects and best dose of dasatinib when given together with osimertinib and how well they work in treating patients with non-small cell lung cancer with EGFR mutations that has spread to other places in the body and usually cannot be cured or controlled with treatment. Dasatinib and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: MedStar Georgetown University Hospital, Washington, District of Columbia

  • Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML

    The primary objective of the Phase 1b study is to determine the dose-limiting toxicity (DLT) and maximal tolerated dose (MTD) of BP1001 and Dasatinib (Das) in patients with Philadelphia chromosome positive (Ph+) Chronic Myelogenous Leukemia (CML) in accelerated or blast phase. The primary objective of the Phase IIa study is to assess the efficacy of the combination of BP1001 and Das in patients with Ph+ CML.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Personalized Kinase Inhibitor Therapy Combined with Chemotherapy in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia

    This phase IB trial studies the feasibility of using a functional laboratory based study to determine how well the test can be used to select personalized kinase inhibitor therapy in combination with standard chemotherapy in treating patients with newly diagnosed acute myeloid leukemia (AML). It also evaluates safety and potential efficacy. Kinase inhibitor is a type of substance that blocks an enzyme called a kinase. Human cells have many different kinase enzymes, and they help control important cell functions. Certain kinases are more active in some types of cancer cells and blocking them may help keep the cancer cells from growing. Testing samples of blood from patients with AML in the laboratory with kinase inhibitors may help determine which kinase inhibitor has more activity against cancer cells and which one should be combined with standard of care chemotherapy. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving a personalized kinase inhibitor therapy combined with standard chemotherapy may be a better treatment for AML.
    Location: OHSU Knight Cancer Institute, Portland, Oregon

  • Dasatinib in Treating Patients with nEGFR Positive Stage I-III Triple-Negative Breast Cancer

    This phase II trial studies how well dasatinib works in treating patients with nuclear (n)EGFR stage I-III triple-negative breast cancer. nEGFR promotes tumor growth. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: University of Wisconsin Hospital and Clinics, Madison, Wisconsin

  • Dasatinib or Nilotinib Followed by Imatinib Mesylate in Treating Patients with Newly Diagnosed, Previously Untreated, Chronic Phase Chronic Myeloid Leukemia

    This phase II trial studies how well dasatinib, nilotinib, and imatinib mesylate works in treating patients with newly diagnosed, previously untreated chronic myeloid leukemia in which fewer than 10% of the cells in the blood and bone marrow are blast cells (immature blood cells) (chronic phase). Dasatinib, nilotinib, and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: Emory University Hospital / Winship Cancer Institute, Atlanta, Georgia

  • Dasatinib in Treating Patients with Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia

    This phase IV trial studies dasatinib in treating patients with Philadelphia chromosome positive or BCR-ABL1 positive early chronic phase chronic myelogenous leukemia. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Ruxolitinib Phosphate, Dasatinib, and Dexamethasone in Treating Patients with Philadelphia Chromosome-Positive or Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

    This phase I trial studies the side effects and best dose of ruxolitinib phosphate when given together with dasatinib and dexamethasone in treating patients with Philadelphia chromosome-positive or Philadelphia chromosome-like acute lymphoblastic leukemia or chronic myelogenous leukemia. Ruxolitinib phosphate and dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunosuppressive therapy, such as dexamethasone, is used to decrease the body's immune response and may improve bone marrow function. Giving ruxolitinib phosphate together with dasatinib and dexamethasone may be a better treatment for acute lymphoblastic leukemia or chronic myelogenous leukemia.
    Location: Memorial Sloan-Kettering Cancer Center, New York, New York

  • Ruxolitinib Phosphate or Dasatinib with Chemotherapy in Treating Patients with Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

    This phase I / II trial studies the side effects and best dose of ruxolitinib phosphate and how well it works compared to dasatinib when given with chemotherapy in treating patients with Philadelphia chromosome-like acute lymphoblastic leukemia that has come back or has not responded to treatment. Ruxolitinib phosphate and dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving ruxolitinib phosphate or dasatinib with chemotherapy works better in treating patients with previously treated acute lymphoblastic leukemia.
    Location: M D Anderson Cancer Center, Houston, Texas


1 2 Next >